Earnings ·
Dogwood Therapeutics reported a net loss of $11.5 million for the second quarter ended June 30, 2026, or $0.34 per…
DWTXDogwood Therapeutics, Inc.
Dogwood Therapeutics reported a net loss of $11.5 million for the second quarter ended June 30, 2026, or $0.34 per share, driven by a $9.2 million non-cash IPR&D impairment charge and increased R&D expenses of $3.2 million. The company announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million to Dogwood and its CVR holders. Halneuron Phase 2b trial enrollment reached 217 patients, with top-line results expected in fall 2026, while SP16 received FDA IND approval for a fully NCI-funded Phase 1b study beginning in the second half of 2026. Cash on hand stands at $9.6 million, providing runway through the fourth quarter 2026. Dogwood Therapeutics is a biopharmaceutical company developing non-opioid medicines to treat pain and neuropathic disorders.